Dominant negative activity of thyroid hormone receptor variant α2 and interaction with nuclear corepressors

Molecular and Cellular Endocrinology

Volumn 149, Issue 1-2, 1999, Pages 107-114

  Burgos Trinidad, María ^a   Koenig, Ronald J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Corepressors; Dominant negative activity; Ninth heptad; Retinoid X receptor; Thyroid hormone receptor

Indexed keywords

GLUTATHIONE TRANSFERASE; NUCLEAR PROTEIN; RETINOID X RECEPTOR; THYROID HORMONE RECEPTOR;

ARTICLE; GENETIC TRANSFECTION; HORMONE RESPONSIVE ELEMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RECEPTOR GENE;

ANIMALS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; MICE; MUTATION; NUCLEAR PROTEINS; RATS; RECEPTORS, THYROID HORMONE; REPRESSOR PROTEINS; TRANSFECTION; VARIATION (GENETICS);

EID: 0033602429     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00253-6     Document Type: Article

References (42)

1. Au-Fliegner M., Helmer E., Casanova J., Raaka B. M., Samuels H.H. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. Mol. Cell. Biol. 13:1993;5725-5737.
2. 3) receptor dimers defines wild type T3 response elements. Mol. Endocrinol. 6:1992;502-514.
3. Brent G.A., Harney J.W., Chen Y., Warne R.L., Moore D.D., Larsen P.R. Mutations of the rat growth hormone promoter which increase and decrease response to thyroid hormone define a consensus thyroid hormone response element. Mol. Endocrinol. 3:1989;1996-2004.
4. Chen J.D., Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 377:1995;454-457.
5. Clifton-Bligh R.J., De Zegher F., Wagner R.L., Collingwood T.N., Francois I., Van Helvoirt M., Fletterick R.J., Chatterjee V.K.K. A novel TRβ mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation. Mol. Endocrinol. 12:1998;609-621.
6. Damm K., Evans R.M. Identification of a domain required for oncogenic activity and transcriptional suppression by v-erbA and thyroid-hormone receptor α Proc. Natl. Acad. Sci. USA. 90:1993;10668-10672.
7. Damm K., Beug H., Graf T., Vennstrom B. A single point mutation in erbA restores the erythroid transforming potential of a mutant avian erythroblastosis virus (AEV) defective in both erbA and erbB oncogenes. EMBO J. 6:1987;375-382.
8. Farsetti A., Lazar J., Phyillaier M., Lippoldt R., Pontecorvi A., Nikodem V.M. Active repression by thyroid hormone receptor splicing variant α2 requires specific regulatory elements in the context of native triiodothyronine-regulated gene promoters. Endocrinology. 138:1997;4705-4712.
9. Farsetti A., Desvergne B., Hallenbeck P., Robbins J., Nikodem V.M. Characterization of myelin basic protein thyroid hormone response element and its function in the context of native and heterologous promoter. J. Biol. Chem. 267:1992;15784-15788.
10. Forman B.M., Samuels H.H. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. Mol. Endocrinol. 4:1990;1293-1301.
11. Hörlein A.J., Näär A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Söderström M., Glass C.K., Rosenfeld M.G. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377:1995;397-404.
12. Ikeda M., Wilcox E.C., Chin W.W. Different DNA elements can modulate the conformation of thyroid hormone receptor heterodimer and its transcriptional activity. J. Biol. Chem. 271:1996;23096-23104.
13. Katz D., Berrodin T.J., Lazar M.A. The unique C-termini of the thyroid hormone receptor variant, c-erbA α2, and thyroid hormone receptor α1 mediate different DNA-binding and heterodimerization properties. Mol. Endocrinol. 6:1992;805-814.
14. Katz D., Lazar M.A. Dominant negative activity of an endogenous thyroid hormone receptor variant (α2) is due to competition for binding sites on target genes. J. Biol. Chem. 268:1993;20904-20910.
15. Katz R.W., Koenig R. J. Non-biased identification of DNA sequences which bind thyroid hormone receptor α1 with high affinity. J. Biol. Chem. 268:1993;19392-19397.
16. 3 signalling. Nature. 355:1992;446-449.
17. Koenig R.J., Lazar M.A., Hodin R.A., Brent G.A., Larsen P.R., Chin W.W., Moore D.D. Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing. Nature. 337:1989;659-661.
18. Koenig R.J., Warne R.L., Brent G.A., Harney J.W., Larsen P.R., Moore D.D. Isolation of a cDNA clone encoding a biologically active thyroid hormone receptor. Proc. Natl. Acad. Sci. USA. 85:1988;5031-5035.
19. Kurokawa R., Söderström M., Hörlein A., Halachmi S., Brown M., Rosenfeld M.G., Glass C.K. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 377:1995;451-454.
20. Lazar M.A. Thyroid hormone receptors: Multiple forms, multiple possibilities. Endocrine Rev. 14:1993;184-193.
21. Lazar M.A., Hodin R.A., Chin W.W. Human carboxyl-terminal variant of α-type c-erbA inhibits trans-activation by thyroid hormone receptors without binding thyroid hormone. Proc. Natl. Acad. Sci. USA. 86:1989;7771-7774.
22. Lazar M.A., Hodin R.A., Darling D.S., Chin W.W. Identification of a rat c-erbAα-related protein which binds deoxyribonucleic acid but does not bind thyroid hormone. Mol. Endocrinol. 2:1988;893-901.
23. Leid M., Kastner P., Lyons R., Nakshatri H., Saunders M., Zacharewski T., Chen J.Y., Staub A., Garnier J.M., Mader S., Chambon P. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell. 68:1992;377-395.
24. Liu R.-T., Suzuki S., Miyamoto T., Takeda T., Ozata M., DeGroot L.J. The dominant negative effect of thyroid hormone receptor splicing variant α2 does not require binding to a thyroid response element. Mol. Endocrinol. 9:1995;86-95.
25. Nagaya T., Jameson J.L. Distinct dimerization domains provide antagonist pathways for thyroid hormone receptor action. J. Biol. Chem. 268:1993;24278-24282.
26. O'Donnell A.L., Koenig R.J. Mutational analysis identifies a new functional domain of the thyroid hormone receptor. Mol. Endocrinol. 4:1990;715-720.
27. Prost E., Koenig R.J., Moore D.D., Larsen P.R., Whalen R.G. Multiple sequences encoding potential thyroid hormone receptors isolated from mouse skeletal muscle cDNA libraries. Nucl. Acids Res. 16:1988;6248.
28. Prost E., Moore D.D. CAT vectors for analysis of eukaryotic promoters and enhancers. Gene. 45:1986;107-111.
29. Reginato M.J., Zhang J.S., Lazar M.A. DNA-independent and DNA-dependent mechanisms regulate the differential heterodimerization of the isoforms of the thyroid hormone receptor with retinoid X receptor. J. Biol. Chem. 271:1996;28199-28205.
30. Ribeiro R.C.J., Kushner P.J., Baxter J.D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 46:1995;443-453.
31. Ron D., Dressler H. pGSTag-A versatile bacterial expression plasmid for enzymatic labeling of recombinant proteins. Biotechniques. 13:1992;866-869.
32. Smith D.B., Johnson K.S. Single step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 67:1988;31-40.
33. Tagami T., Jameson J.L. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone. Endocrinology. 139:1998;640-650.
34. Tagami T., Kopp P., Johnson W., Arseven O.K., Jameson J.L. The thyroid hormone receptor variant α2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressors. Endocrinology. 139:1998;2535-2544.
35. Tagami T., Madison L.D., Nagaya T., Jameson J.L. Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol. Cell. Biol. 17:1997;2642-2648.
36. Tsai M., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem. 63:1994;451-486.
37. Williams G.R., Zavacki A.M., Harney J.W., Brent G.A. Thyroid hormone receptor binds with unique properties to response elements that contain hexamer domains in an inverted palindrome arrangement. Endocrinology. 134:1994;1888-1896.
38. Yang Y., Burgos-Trinidad M., Wu Y., Koenig R.J. Thyroid hormone receptor variant α2: role of the ninth heptad in DNA binding, heterodimerization with retinoid X receptors and dominant negative activity. J. Biol. Chem. 271:1996;28235-28242.
39. 3 receptors and transcriptional corepressors. Mol. Endocrinol. 11:1997;470-480.
40. Yu V.C., Delsert C., Andersen B., Holloway J.M., Devary O.V., Naar A.M., Kim S.Y., Boutin J.M., Glass C.K., Rosenfeld M.G. RXRβ - a coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell. 67:1991;1251-1266.
41. Zamir I., Harding H.P., Atkins G.B., Hörlein A., Glass C.K., Rosenfeld M.G., Lazar M.A. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol. Cell. Biol. 16:1996;5458-5465.
42. Zhang J.S., Zamir I., Lazar M.A. Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression. Mol. Cell. Biol. 17:1997;6887-6897.